Cardiology/Vascular Diseases | Approved Drugs

Pfizer Inc

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Contact Supplier

Virtual Booth

Pharmavenue, Spain 2020

Participation Not Confirmed

Update your events

Premier ProvideGx Program Partners with Pfizer

Lead Product(s): Ibutilide

Therapeutic Area: Cardiology/Vascular Diseases

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: Premier Intermediates Pvt.Ltd.

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Partnership February 19, 2020

Details:

Premier’s ProvideGx program identifies safe, high-quality supply sources for drugs that are or may be at risk of being added to the national drug shortage list.

Esperion Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

Pharmavenue, Spain 2020

Participation Not Confirmed

Update your events

Esperion Strikes Japan Deal for 'Goldilocks' Cholestrol Drug, Bags $60m Cash as Pandemic Forces Virtual Us Rollout

Lead Product(s): Bempedoic Acid,Ezetimibe

Therapeutic Area: Cardiology/Vascular Diseases

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: Otsuka Pharmaceutical

Deal Size: $510.0 million Upfront Cash: $60.0 million

Deal Type: Collaboration April 20, 2020

Details:

The collaboration advances the commitment of both companies to provide cost-effective, oral, once-daily, non-statin LDL-cholesterol lowering medicines for hypercholesterolemia patients in Japan.

Esperion Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

Pharmavenue, Spain 2020

Participation Not Confirmed

Update your events

Esperion Announces European Commission Approval of the NUSTENDI Tablet for Hypercholesterolemia and Mixed Dyslipidemia

Lead Product(s): Bempedoic Acid,Ezetimibe

Therapeutic Area: Cardiology/Vascular Diseases

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 06, 2020

Details:

NUSTENDI is approved for patients who require additional Ldl-Cholesterol lowering on a background statin, other lipid-lowering therapies, or considered statin intolerant.

Correvio Pharma

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CANADA Canada

Post An Enquiry

Virtual Booth

Pharmavenue, Spain 2020

Participation Not Confirmed

Update your events

Correvio Partners with Hong Kong Teson Pharma Limited

Lead Product(s): Tirofiban Hydrochloride

Therapeutic Area: Cardiology/Vascular Diseases

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: Hong Kong Teson Pharma

Deal Size: $3.5 million Upfront Cash: $3.0 million

Deal Type: Agreement March 10, 2020

Details:

The investment vehicle, which LSP claims is the largest of its type in Europe, is bigger than the VC shop’s three previous life science funds combined.

UCB Pharma S.A.

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

BELGIUM Belgium

Post An Enquiry

Virtual Booth

Pharmavenue, Spain 2020

Participation Not Confirmed

Update your events

Advanz Pharma Announces Definitive Agreement to Acquire The Rights To A Portfolio Of Alprostadil Products

Lead Product(s): Alprostadil

Therapeutic Area: Cardiology/Vascular Diseases

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: Advanz Pharma

Deal Size: $98.0 million Upfront Cash: $84.0 million

Deal Type: Agreement March 06, 2020

Details:

The alprostadil product portfolio consists of two established, niche, injectable Prostaglandin E1 formulations for the treatment of erectile disfunction and peripheral arterial occlusive disease.

Novartis Pharmaceuticals Corporation

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Switzerland

Post An Enquiry

Virtual Booth

Pharmavenue, Spain 2020

Participation Not Confirmed

Update your events

Otsuka enters into co-promotion agreement for angiotensin receptor neprilysin inhibitor (ARNI) LCZ696 in Japan

Lead Product(s): Sacubitril valsartan sodium hydrate

Therapeutic Area: Cardiology/Vascular Diseases

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: Otsuka Chemical Co Ltd

Deal Size: Undisclosed Upfront Cash: $90.0 million

Deal Type: Agreement March 02, 2020

Details:

Under the terms of this agreement, Novartis Pharma and Otsuka will jointly undertake the promotion of LCZ696 to healthcare practitioners in Japan.

GlaxoSmithKline plc

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United Kingdom

Post An Enquiry

Virtual Booth

Pharmavenue, Spain 2020

Participation Not Confirmed

Update your events

STADA becomes a major Consumer Healthcare player by acquiring 15 well-established GSK brands

Lead Product(s): Troxerutin

Therapeutic Area: Cardiology/Vascular Diseases

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: STADA Production Ireland Ltd., trading as Suir Pharma Ireland

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Acquisition February 24, 2020

Details:

The transaction represents 15 brands including Venoruton, for venous treatment; Coldrex cold remedy; Cetebe vitamin C supplements; Mebucaine sore throat range and Tavegyl allergy brand.

AstraZeneca PLC

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United Kingdom

Post An Enquiry

Virtual Booth

Pharmavenue, Spain 2020

Participation Not Confirmed

Update your events

AstraZeneca divests rights to established hypertension medicines

Lead Product(s): Propranolol

Therapeutic Area: Cardiology/Vascular Diseases

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: ATNAHS PHARMA UK LIMITED

Deal Size: $390.0 million Upfront Cash: $350.0 million

Deal Type: Divestment January 27, 2020

Details:

AstraZeneca is seeking $350 million from Atnahs Pharma for global trade rights to a series of five hypertension drugs off-patent: Inderal, Tenormin, Tenoretic, Zestril and Zestoretic.